BevacizumabIn First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma

被引：0
|
作者：
James E. Frampton
Gillian M. Keating
机构：
[1] Wolters Kluwer Health ¦ Adis,
[2] Wolters Kluwer Health,undefined
来源：
BioDrugs | 2008年 / 22卷
关键词：
Vascular Endothelial Growth Factor; Renal Cell Carcinoma; Bevacizumab; Sorafenib; Erlotinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
▴ Bevacizumab, an anti-vascular endothelial growth factor recombinant humanized monoclonal antibody, directly inhibits tumor angiogenesis and hence tumor growth.
引用
收藏
页码：113 / 120
页数：7
相关论文
共 50 条
  • [31] Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma
    Rini, Brian I.
    Gruenwald, Victor
    Jonasch, Eric
    Fishman, Mayer N.
    Tomita, Yoshihiko
    Michaelson, M. Dror
    Tarazi, Jamal
    Cisar, Laura
    Hariharan, Subramanian
    Bair, Angel H.
    Rosbrook, Brad
    Hutson, Thomas E.
    TARGETED ONCOLOGY, 2017, 12 (03) : 333 - 340
  • [32] Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma A Review
    George, Saby
    Rini, Brian I.
    Hammers, Hans J.
    JAMA ONCOLOGY, 2019, 5 (03) : 411 - 421
  • [33] Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain
    Guillermo Villa
    Luis-Javier Hernández-Pastor
    BMC Cancer, 13
  • [34] Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma
    Bensimon, Arielle G.
    Zhong, Yichen
    Swami, Umang
    Briggs, Allison
    Young, Joshua
    Feng, Yuan
    Song, Yan
    Signorovitch, James
    Adejoro, Oluwakayode
    Chakravarty, Abhiroop
    Chen, Mei
    Perini, Rodolfo F.
    Geynisman, Daniel M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (09) : 1507 - 1517
  • [35] Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients
    Bellmunt, Joaquim
    Fishman, Mayer
    Eisen, Timothy
    Quinn, David
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (06) : 825 - 835
  • [36] A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma
    Elodie Jobard
    Ellen Blanc
    Sylvie Négrier
    Bernard Escudier
    Gwenaelle Gravis
    Christine Chevreau
    Bénédicte Elena-Herrmann
    Olivier Trédan
    British Journal of Cancer, 2015, 113 : 1148 - 1157
  • [37] Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options
    Schmidt, Andrew
    Azad, Arun
    Goh, Jeffrey
    Harris, Carole
    Joshua, Anthony M.
    Weickhardt, Andrew
    Krieger, Laurence
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 3 - 10
  • [38] First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
    Hahn, Andrew W.
    Klaassen, Zachary
    Agarwal, Neeraj
    Haaland, Benjamin
    Esther, John
    Ye, Xiang Y.
    Wang, Xuechen
    Pal, Sumanta K.
    Wallis, Christopher J. D.
    EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (06): : 708 - 715
  • [39] A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma
    Jobard, Elodie
    Blanc, Ellen
    Negrier, Sylvie
    Escudier, Bernard
    Gravis, Gwenaelle
    Chevreau, Christine
    Elena-Herrmann, Benedicte
    Tredan, Olivier
    BRITISH JOURNAL OF CANCER, 2015, 113 (08) : 1148 - 1157
  • [40] Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report
    Wei, Hang-Ping
    Mao, Jie
    Hu, Zu-Liang
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (11) : 3593 - 3600
12345